Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
- Leslie M. Randall
- , Michael W. Sill
- , Robert A. Burger
- , Bradley J. Monk
- , Barbara Buening
- , Joel I. Sorosky
Research output: Contribution to journal › Article › peer-review
16
Link opens in a new tab
Scopus
citations